The tetracycline-regulatable system (TRS) has become a that, at 1000 ng/ml, all the analogues have similar widely adopted tool for modification of gene expression efficiencies in down-regulating the system in a given time. and analysis of gene function in mammalian cells, plants
Controlling the level and timing of transgene expression monly used in clinical or veterinary settings. 15 The favourable pharmacokinetics and pharmacodynamics of is clearly desirable in many gene therapy applications. Successful treatment of certain disease states requires a doxycycline have encouraged the use of this agent for most of the clinical conditions requiring tetracycline. 16 specific dose of the therapeutic gene product 1,2 and excessive production of some proteins may prove to be Moreover, doxycycline has recently been used to achieve quantitative regulation of both tTA and reverse tTA in toxic. 3 A regulatable system that can offer tight control in response to pharmacological agents that can be safely transgenic mice. 17 Here, we study the kinetics of repression/induction of the TRS in response to the cliniand repetitively administered is clearly of value in modifying specific therapies. Although a variety of regulatcally used minocycline and doxycycline, and to tetracycline and anhydrotetracycline. able promoters have been developed, most require inducible agents that are associated with adverse effects
The kinetics of TRS repression in response to tetracycline analogues were compared to that of tetracycline at on mammalian cells. 4 The TRS 5 avoids the problems related to many of the other systems by offering substan-1000 ng/ml. As can be seen from Figure 2 , this repression is very similar for doxycycline, minocycline, anhydrotial regulation of transgene expression in response to concentrations of tetracycline that cause little cytotoxicity in tetracycline and tetracycline. Oxytetracycline, also, follows the same kinetics of TRS repression as seen in mammalian cells. Since its original description, it has emerged as an invaluable tool for tight and reversible Figure 2 (data not shown). All the agents are capable of repressing the tRP to the same degree within 4 h of treatcontrol of transgene expression, both in vitro and in vivo. 6 The popularity of the system for in vivo gene regulation ment when the mGM-CSF level is reduced to about 9% of its control. Furthermore, the degrees of repression remain in transgenic mice [7] [8] [9] [10] [11] and its potential applications in gene therapy, 12-14 necessitates a better understanding of comparable for all the later times. The system reaches its basal expression within 18-24 h when the mGM-CSF this system in response to tetracycline derivatives available for clinical use. Despite the existence of over 1000 level is about 0.22% of its control. This rapid repression to basal expression may reflect the short half-life of tetracycline derivatives, only seven of these are commGM-CSF mRNA (1.5 h) 18 rather than degradation of mGM-CSF protein which is extremely stable in culture medium (data not shown). Hence, despite having differ- tRP is fully repressed at both 100 and 1000 ng/ml with partial activity of the promoter occurring at 10 pg/ml to 100 ng/ml. Minocycline also fully represses the promoter at 100 and 1000 ng/ml with partial activity of the promoter seen at 100 pg/ml to 100 ng/ml. As is evident at lower concentrations, minocycline is less efficient in inactivating tTA than anhydrotetracycline and more efficient than tetracycline. Doxycycline causes maximum repression of the tRP at 10, 100 and 1000 ng/ml and partial activity of the promoter occurs at 10 pg/ml to 10 ng/ml. Finally, oxytetracycline causes maximum repression of tRP at 1000 ng/ml and partial activity at concentrations below this value (data not shown). Our set-up appears to be slightly less sensitive than the observations previously made using anhydrotetracycline 21 and cell lines, the reporter genes, the nature of collection and analysis of the reporter genes and/or the order of regulation of the two approaches. centrations of these analogues are administered and
The behaviour of the system in response to the withmaintained), any of these agents is capable of rapidly drawal of tetracycline and its derivatives is more distincsuppressing tRP to its fully repressed level.
tive. When pretreated with 1000 ng/ml of tetracycline or Comparing the degree of repression of tRP in response its analogues, there is a characteristic delay in resumption to tetracycline derivatives indicates that the level of reguof tRP activity depending on the analogue used. For lation depends on both the concentration and intrinsic tetracycline, promoter activity is resumed during the first properties of a given analogue (Figure 3a -d, 0.0 h). For 24 h of tetracycline removal and it reaches near-optimal tetracycline, maximum repression occurs at 100-activity at 48 h (Figure 3a ), consistent with previous 1000 ng/ml, with partial activity of the tRP occurring at 100 pg/ml to 100 ng/ml. For anhydrotetracycline, the observations. in a shorter delay in resumption of tRP activity, with activity is resumed similarly after the removal of both minocycline and doxycycline, even though minocycline optimal expression being reached at about 36 h (data not shown). In contrast, the TRS takes much longer to regain has a far lower K A for tetR than doxycycline. These observations suggest the importance of other factors, activity after removal of the other three analogues. The TRS is completely inactive at 48 h after removal of both especially concentration of the analogue within the cell. The in vitro and in vivo intracellular concentration of a anhydrotetracycline and minocycline, and at 72 h after the removal of doxycycline. When pretreated with anhytetracycline may be influenced by the duration of treatment, concentration of the analogue administered, lipodrotetracycline, it takes the tRP 144 h to resume nearoptimal activity (Figure 3b) . Both minocycline and doxyphilicity, protein binding characteristics of the analogue and transport mechanisms across the cell membrane. cycline behave similarly in this respect, with TRS taking about 192 h (estimated from the data) (Figure 3c ) and
Other processes that will affect this are pharmacokinetics and pharmacodynamics of the analogue in animals. Min-216 h to recover near-optimal activity (Figure 3d ) when pretreated with these agents, respectively. The above ocycline and doxycycline are 10-fold and five-fold 19 more lipophilic than tetracycline and can achieve higher conresults for 1000 ng/ml of the tetracycline, anhydrotetracycline, minocycline and doxycycline are summarised in centrations in many tissues than in serum in vivo. 27 Furthermore, doxycycline has been shown to reach higher Figure 3e . For all the tetracyclines used, promoter activity is regained earlier when pretreated with lower concenintracellular concentrations in red blood cells and in neutrophils than that of the surrounding culture medium. 28 trations. Thus, there is a temporal delay in resumption of promoter activity based on the type and the dose of the Also, anhydrotetracycline 20 is more lipophilic and thus has a higher level of cellular/tissue penetration than analogue used for repression. Furthermore, at any given concentration, the activity of tRP is resumed linearly over tetracycline. Thus, the lipophilic property of the agents may explain why lower concentrations of these anatime (Figure 3f ).
To ensure that the above observation is not due to any logues can achieve the same degree of repression as higher concentrations of tetracycline. This property may residual analogue remaining in the wells, cells pretreated for 72 h with 100 ng/ml of doxycycline were detached, also explain why tetracycline is more efficient in repressing tRP than the less lipophilic oxytetracycline. 29 washed extensively and re-plated into new culture plates. These cells produced exactly the same results as seen in Both the order of potency and the pattern of resumption of tRP activity resemble the pattern of binding of these Figure 3 (data not shown). Our results are further substantiated by noting a similar observation when using agents to serum proteins (20-35% for oxytetracycline, 29 25-65% for tetracycline, 75-80% for minocycline 27 and doxycycline to manipulate the surface expression of a chimeric molecule in Jurkat cells 23 and to regulate a 80-90% for doxycycline 29 ) . Considering this, the affinity of these analogues for intracellular proteins may be at modified TRS in AM12 cells. 24 Both repression and induction of the TRS depend on least partly responsible for the differing concentrations of these agents within the cell and thus for the pattern of the concentration of the tetracycline analogue within a cell and the efficiency of the analogue in reducing tetRresumption of tRP activity. Overall our findings indicate that the different propertet operator interaction. The efficiency of an analogue, given as the concentration of the analogue resulting in ties of tetracycline analogues can be employed in planning a desired course of transgene regulation. These are 50% reduction in tetR-tet operator interaction, is 2.2 × 10 −6 m for tetracycline, 0.09 × 10 −6 m for anhydroimportant for both the use of the TRS system in in vitro and in vivo applications. For example, in many in vitro or tetracycline, and 0.14 × 10 −6 m for doxycycline. For most tetracycline analogues, this efficiency has been shown to in vivo applications, a more rapid resumption of tRP activity may be achieved by using oxytetracycline rather be correlated with the association equilibrium constant (K A ) of the analogue for tetR. 25 , 26 respectively. K A for minocycline is lower than that of 4-epi-7-chloro-tetracycof doxycycline is clearly more convenient. Both doxycycline and minocycline are used extensively in clinical setline which is about 0.4 × 10 9 m −1 . 26 Our observed order of analogue potency (doxycycline Ͼ anhydrotetracycline Ͼ tings. These tetracyclines, with their efficient oral absorption (93-100%), 29, 30 long half-life (14-22 h for doxycycline minocycline Ͼ tetracycline Ͼ oxytetracycline) does not directly correlate with the order of efficiency or the and 11-13 h for minocycline), 30, 31 excellent tissue penetration and hepatic excretion, 27, 30 are ideal agents for in association equilibrium constants for tetR. Despite having a higher efficiency and K A than doxycycline, anhydrovivo control of TRS. The ability of doxycycline to switch off the promoter over the range of 10-1000 ng/ml could tetracycline is less effective than this agent in repressing tRP. Also, minocycline has a significantly lower K A than be of importance in vivo where the activity of the tRP can be maintained fully repressed so long as the tissue tetracycline but is more efficient in repressing the system. In addition, the pattern of resumption of tRP activity concentration of doxycycline remains above 10 ng/ml. Administration of 200 mg of doxycycline or minocycline (earliest for oxytetracycline, followed by tetracycline, anhydrotetracycline, minocycline and doxycycline) does orally to humans produces peak serum concentrations of 3-5 g/ml after 2 h, 18 with a plateau-shaped plasma connot correlate with the association equilibrium constants or our observed order of potency. In this respect, it is centration curve 27 that falls below 1 g/ml after approximately 24 h for minocycline 30 and 50 h for doxycycline. 32 interesting to realise that anhydrotetracycline results in a shorter delay in resumption of tRP activity than minocycThis, together with the higher tissue to plasma concentration ratio of doxycycline and minocycline, ensures that line or doxycycline, despite having much higher K A for tetR compared with these derivatives. Moreover, tRP the expression of a given gene can be kept switched off 
